MedImmune keeps market perform rating by JMP

JMP Securities analyst Adam Cutler reiterated MedImmune Inc. at its market perform rating on news that the company reported fourth-quarter 2005 financial results. Total revenue of $492 million missed Jefferies' estimate of $499 million and the Street consensus estimate of $516 million. Lower-than-expected FluMist revenue was a main factor in the revenue shortfall. MedImmune issued 2006 earnings-per-share guidance of $0.40 to $0.45, below the analyst's and the Street expectations of $0.46 Shares of the Gaithersburg, Md., biotechnology company were down 40 cents, or 1.22%, at $32.50 on volume of 3,459,899 shares versus the three-month running average of 2,048,990 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.